Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:adalimumab-adbm
|
| gptkbp:approvalYear |
2017-08-25
|
| gptkbp:ATCCode |
L04AB04
|
| gptkbp:biosimilar |
gptkb:Humira
|
| gptkbp:brand |
gptkb:Cyltezo
|
| gptkbp:drugClass |
TNF inhibitor
|
| gptkbp:genericName |
gptkb:adalimumab-adbm
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cyltezo
|
| gptkbp:indication |
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease gptkb:psoriatic_arthritis ulcerative colitis rheumatoid arthritis ankylosing spondylitis plaque psoriasis |
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:bfsParent |
gptkb:Boehringer_Ingelheim
|
| gptkbp:bfsLayer |
6
|